The Moroccan government approved a new decree on Wednesday aimed at reforming how public sale prices (PPV) for both locally manufactured and imported medications are determined. Presented by the Minister of Health and Social Protection, the legislation seeks to lower drug costs for citizens, alleviate the financial burden on insured patients, and support the long-term sustainability of the Mandatory Health Insurance (AMO) system.
Objectives of Decree No. 2.25.631
The newly adopted decree, identified as No. 2.25.631, amends and supplements the existing framework established by Decree No. 2-13-852, which has governed medication pricing since December 2013. According to the government spokesperson, the primary goal of this regulatory update is to improve patient access to essential treatments by reducing retail prices.
Beyond immediate cost relief for patients, the government aims to strengthen the financial health of the AMO regime. By lowering the expenses associated with medication procurement, officials intend to ensure that the insurance system remains viable for the long term. The decree also includes provisions designed to boost the competitiveness of the domestic pharmaceutical industry, fostering its growth and reinforcing the Kingdom’s sovereignty in medication production.
Did You Know?
The regulatory changes introduced this Wednesday serve as an update to a legal framework that has been in place since December 18, 2013, specifically targeting the modalities for setting the public sale price of pharmaceutical products.
Legislative Status and Pending Actions
While the cabinet moved forward with the pricing decree, it opted to delay the review of a separate piece of legislation. The Council of Government reported that it has postponed the examination of draft decree No. 2.26.549, which concerns the application of Article 30 of Law No. 27.26. That law is intended to modify and supplement the existing Code of Medicine and Pharmacy, known as Law No. 17.04.
Frequently Asked Questions
What is the purpose of the newly adopted decree?
The decree aims to lower the public sale price of medications, improve citizen access to treatments, reduce financial strain on insured patients, and support the financial stability of the AMO system.
Does this affect imported medications?
Yes, the legislation applies to the conditions and modalities for fixing the price of both locally manufactured and imported medications.
What happened to the proposed changes to the Code of Medicine and Pharmacy?
The Council of Government has officially postponed the examination of draft decree No. 2.26.549, which relates to the application of Article 30 of the law governing the Code of Medicine and Pharmacy.
How might these pricing adjustments influence the availability of specialized medications in local pharmacies?
Related reading